Schizophrenia Research
Volume 81, Issue 1 , Pages 29-39 , 1 January 2006

Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes

  • Lili C. Kopala

      Affiliations

    • Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Center for Complex Disorders, University of British Columbia, 15521 Russell Ave, White Rock, B.C., V4B 2R4 Canada. Tel.: +1 604 535 4500x779; fax: +1 604 538 4277.
    • ,
  • Kimberley P. Good

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • Heather Milliken

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • Christine Buiteman

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • Hazel Woodley

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • Qing Rui

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • David Whitehorn

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • Leslie Love

      Affiliations

    • Syreon Corporation, Vancouver, BC, Canada
    • ,
  • Robert Balshaw

      Affiliations

    • Syreon Corporation, Vancouver, BC, Canada
    • ,
  • Ivan Kiss

      Affiliations

    • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    • ,
  • William G. Honer

      Affiliations

    • Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

Received 27 June 2005 ,Revised 25 August 2005 ,Accepted 1 September 2005.

References 

  1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990;3:247–251
  2. Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can. J. Psychiatry. 2003;48:272–275
  3. Allison D, Mentore J, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  4. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth edition. Washington, DC: American Psychiatric Association; 1994;
  5. Benton A. A Test of Three Dimentional Constructural Praxis: Manual. University of Iowa: Neurosensory Center Publication; 1974;
  6. Benton A, Hamsher K. Multilingual Aphasia Examination. Iowa City, Iowa: AJA Associates; 1989;
  7. Bilder R, Goldman R, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2002;159:1018–1028
  8. Cornblatt B, Lenzenweger M, Erlenmeyer-Kimling L. The continuous Performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989;29:65–85
  9. Chouinard G, Ross-Chouinard A, Annable L, et al. The extrapyramidal symptom rating scale. Can. J. Neurol. Sci. 1980;7:233
  10. Freedman M, Black S, Ebert P, et al. Orbitofrontal function, object alternation, and perseveration. Cereb. Cortex. 1998;8:18–27
  11. Good K, Kiss I, Buiteman C, et al. Improvement in cognitive functioning in patients with first episode psychosis during treatment with quetiapine: an interim analysis. Br. J. Psychiatry. 2002;181:45–49
  12. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am. J. Psychiatry. 2002;159:1055–1057
  13. Green M. What are the functional consequences of neurocognitive deficits in schizophrenia. Am. J. Psychiatry. 1996;153:321–330
  14. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, MD: National Institute of Mental Health; 1976;
  15. Harvey P, Green M, McGurk S, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl.). 2003;169:404–411
  16. Heaton R, Chelune G, Talley J, et al. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources; 1993;
  17. Jin H, Meyer J, Jeste D. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry. 2002;14:59–64
  18. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr. Res. 2004;71(2–3):195–212Dec 1
  19. Jones-Gotman M, Milner B. Design fluency: the invention of nonsense drawings after focal cortical lesions. Neuropsychologia. 1977;15:653–674
  20. Kay S. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:262–275
  21. Kopala L, Good K, Fredrikson D, et al. Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. Int. J. Psychiatry Clin. Pract. 1998;2:19–25
  22. Lieberman J, Jody D, Giesler S, et al. Time course and biological correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry. 1993;50:369–376
  23. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry. 2003;160(8):1396–1404Aug
  24. Lezak M. Neuropsychological Assessment. Third edn.. New York: Oxford University Press; 1995;
  25. Manschreck T, Kopala L, Honer W. Neurological comorbidity and features in schizophrenia. In:  Meyer JM,  Nasrallah HA editor. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Press; 2003;p. 185–214
  26. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 1997;58:538–546
  27. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry. 2002;63:425–433
  28. Meyer JM. Cardiovascular illness and hyperlipidemia in patients in schizophrenia. In:  Meyer JM,  Nasrallah H editor. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Press; 2003;p. 59–89
  29. Meyer J, Koro C. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  30. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry. 2004;161(1):116–124Jan
  31. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28:83–96
  32. Nasrallah HA, Targum SD, Tandon R, et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 2005;56(3):273–282
  33. Purdon S, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001;26:137–149
  34. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. Psych. 2003;41:337–343
  35. Reitan R. Validity of the trail making test as an indicator of organic brain damage. Percept. Mot. Skills. 1958;8:271–276
  36. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964;
  37. Sax K, Strakowski S, Keck P. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr. Res. 1998;33:151–155
  38. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry. 2005;162(5):947–953
  39. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 1989;98(4):367–380Nov
  40. Voruganti L, Slomka P, Zabel P, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology. 2001;25:642–650
  41. Velligan D, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr. Res. 2002;53:239–248
  42. Weiden P, Aquila R, Emanuel M, et al. Long-term considerations after switching antipsychotics. J. Clin. Psychiatry. 1998;59:36–49

PII: S0920-9964(05)00391-9

doi: 10.1016/j.schres.2005.09.009

Schizophrenia Research
Volume 81, Issue 1 , Pages 29-39 , 1 January 2006

Article Tools

* Image Usage & Resolution